Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for ABT-346

    Client Email Product

    ABT-346

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    0

    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    0

    API REF. PRICE (USD / KG)

    0

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    18
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
    Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

    https://markets.ft.com/data/announce/full?dockey=600-202404010700BIZWIRE_USPRX____20240401_BW046957-1

    FINANCIAL TIMES
    02 Apr 2024
    Share Share
    Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
    Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting

    https://www.businesswire.com/news/home/20240320913781/en

    BUSINESSWIRE
    20 Mar 2024
    Share Share
    Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
    Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul

    https://www.businesswire.com/news/home/20230928171285/en

    BUSINESSWIRE
    28 Sep 2023
    Share Share
    Antibe Provides Development Update for Otenaproxesul
    Antibe Provides Development Update for Otenaproxesul

    https://www.businesswire.com/news/home/20221012005448/en

    BUSINESSWIRE
    12 Oct 2022
    Share Share
    Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
    Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022

    https://www.businesswire.com/news/home/20220906005405/en

    BUSINESSWIRE
    06 Sep 2022
    Share Share
    Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
    Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results

    https://www.businesswire.com/news/home/20220815005193/en

    BUSINESSWIRE
    15 Aug 2022
    Share Share
    Antibe Therapeutics Outlines Plan for Otenaproxesul's Acute Pain Program
    Antibe Therapeutics Outlines Plan for Otenaproxesul's Acute Pain Program

    https://www.businesswire.com/news/home/20211101005303/en/Antibe-Therapeutics-Outlines-Plan-for-Otenaproxesuls-Acute-Pain-Program

    BUSINESSWIRE
    01 Nov 2021
    Share Share
    Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline
    Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline

    https://www.businesswire.com/news/home/20211014005408/en

    BUSINESSWIRE
    14 Oct 2021
    Share Share
    Antibe Provides Update on Ph2B Dose-Ranging, Efficacy Study for ATB-346
    Antibe Provides Update on Ph2B Dose-Ranging, Efficacy Study for ATB-346

    https://www.businesswire.com/news/home/20190827005253/en/Antibe-Therapeutics-Update-Phase-2B-Dose-Ranging-Efficacy/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIE
    27 Aug 2019
    Share Share
    Ph2B GI Safety Results For ATB-346 Published in British Journal of Pharmacology
    Ph2B GI Safety Results For ATB-346 Published in British Journal of Pharmacology

    https://www.businesswire.com/news/home/20190416005169/en/Phase-2B-GI-Safety-Results-ATB-346-Published/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    PR NEWSWIRE
    16 Apr 2019
    Share Share
    Antibe Therapeutics Announces $5 Million Bought Deal Offering
    Antibe Therapeutics Announces $5 Million Bought Deal Offering

    https://www.businesswire.com/news/home/20190204005726/en

    BUSINESSWIRE
    04 Feb 2019
    Share Share
    Antibe Therapeutics' Successfully Completes Part I of Ph 2B Study for ATB-346
    Antibe Therapeutics' Successfully Completes Part I of Ph 2B Study for ATB-346

    https://www.businesswire.com/news/home/20181127005296/en/Antibe-Therapeutics-Announces-Successful-Completion-Part-Phase/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    28 Nov 2018
    Share Share
    Antibe Therapeutics Receives Approval to Initiate Phase 2B Study for ATB-346
    Antibe Therapeutics Receives Approval to Initiate Phase 2B Study for ATB-346

    https://www.businesswire.com/news/home/20181010005268/en/Antibe-Therapeutics-Receives-Approval-Initiate-Part-Phase

    BUSINESSWIRE
    10 Oct 2018
    Share Share
    Antibe Therapeutics Announces Licensing Deal for Lead Drug in South Korea
    Antibe Therapeutics Announces Licensing Deal for Lead Drug in South Korea

    https://www.businesswire.com/news/home/20180905005326/en

    BUSINESSWIRE
    05 Sep 2018
    Share Share
    Antibe Therapeutics Provides Clinical Development Update on Its Lead Drug
    Antibe Therapeutics Provides Clinical Development Update on Its Lead Drug

    https://www.biospace.com/article/releases/antibe-therapeutics-provides-clinical-development-update-on-its-lead-drug/

    BIOSPACE
    31 Jul 2018
    Share Share
    Antibe Therapeutics Announces Successful Phase 2B GI Safety Study
    Antibe Therapeutics Announces Successful Phase 2B GI Safety Study

    https://www.biospace.com/article/releases/antibe-therapeutics-announces-successful-phase-2b-gastrointestinal-safety-study-for-lead-pain-drug-atb-346/

    Mark Terry BIOSPACE
    20 Mar 2018
    Share Share
    Antibe Therapeutics Announces Enrollment of Final Subjects in Ph2B Gastro
    Antibe Therapeutics Announces Enrollment of Final Subjects in Ph2B Gastro

    https://www.businesswire.com/news/home/20180129005370/en/Antibe-Therapeutics-Announces-Enrollment-Final-Subjects-Phase/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    29 Jan 2018
    Share Share
    Antibe Therapeutics Announces Completion Of Validation Studies Of ATB-346
    Antibe Therapeutics Announces Completion Of Validation Studies Of ATB-346

    http://www.biospace.com/News/basf-and-sumitomo-chemical-company-ltd-explore-in/403672/source=MoreNews

    BIOSPACE
    21 Dec 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search